The INHBE Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of UM-UC-3 human bladder carcinoma cells, engineered for loss-of-function studies of the inhibin beta E subunit. This pool harbors targeted disruption of the INHBE gene, ensuring near-complete absence of functional protein across the heterogeneous cell sample. The polyclonal format preserves genetic variation while enabling robust analysis of INHBE-dependent cellular processes and signaling events in a clinically relevant urothelial carcinoma model.
The parental UM-UC-3 cell line originates from a primary human bladder transitional cell carcinoma and is widely adopted as a model for high-grade invasive urothelial carcinoma. These cells exhibit characteristic features of aggressive bladder cancer, including activated growth factor signaling and invasive potential. As a key resource in bladder cancer research, UM-UC-3 has been extensively characterized for its genomic landscape, drug sensitivity profiles, and pathway dependencies, making it an ideal host for interrogating the role of INHBE in tumorigenesis and progression.
The INHBE gene encodes inhibin beta E, a divergent TGF-?? superfamily ligand that assembles into inhibin and activin complexes to regulate activin/inhibin and SMAD-dependent pathways. INHBE signals through ALK4/ALK5-containing receptor complexes and is modulated extracellularly by follistatin and betaglycan. Knockout of INHBE disrupts cytokine balance, altering phosphorylation of SMAD2/3 and SMAD4 complex formation, which changes transcription of downstream targets including CDKN1A (p21), c-MYC, cyclin D1, and fibronectin. Crosstalk with MAPK/ERK and PI3K/AKT cascades integrates INHBE into proliferation, survival, and epithelial-mesenchymal transition control.
In bladder cancer, INHBE loss may reveal tumor-suppressive or oncogenic functions, given the dual role of TGF-?? signaling. This model enables dissection of INHBE-specific contributions to cell cycle, apoptosis, and metastasis in UM-UC-3 cells, with relevance to bladder cancer progression and metabolic syndrome-associated malignancies. Expression of INHBE in liver and colon cancers suggests that findings may inform cross-tissue mechanisms of TGF-?? superfamily signaling.
Typical applications include functional validation of INHBE in bladder cancer via western blotting for phosphorylated SMAD2/3, RT-qPCR profiling of target genes, and proliferation, migration, invasion, and apoptosis assays. The polyclonal knockout cells support drug target screening and synthetic lethal studies, serving as a versatile platform for TGF-??/activin network analysis in urothelial carcinoma. For technical details, contact Ascent Research.
